Serveur d'exploration sur les relations entre la France et l'Australie

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Immunogénicité And NotP. Begue

List of bibliographic references

Number of relevant bibliographic references: 12.
Ident.Authors (with country if any)Title
001709 Robert J. Norman [Australie] ; Fernando Zegers-Hochschild [Chili] ; Bruno S. Salle [France] ; Jolanda Elbers [Pays-Bas] ; Esther Heijnen [Pays-Bas] ; Maya Marintcheva-Petrova [Pays-Bas] ; Bernadette Mannaerts [Pays-Bas]Repeated ovarian stimulation with corifollitropin alfa in patients in a GnRH antagonist protocol: no concern for immunogenicity
001760 MING QIAO [Australie, France, Thaïlande] ; David Shaw ; Remi Forrat ; Anh Wartel-Tram ; Jean LangPriming Effect of Dengue and Yellow Fever Vaccination on the Immunogenicity, Infectivity, and Safety of a Tetravalent Dengue Vaccine in Humans
001A05 Pierre Van Damme [Belgique] ; Peter Mcintyre [Australie] ; Emmanuel Grimprel [France] ; Sherine Kuriyakose [Inde] ; Jeanne-Marie Jacquet [Belgique] ; Karin Hardt [Belgique] ; Marc Messier [Belgique] ; Olivier Van Der Meeren [Belgique]Immunogenicity of the reduced-antigen-content dTpa vaccine (Boostrix®) in adults 55 years of age and over: A sub-analysis of four trials
002348 F. M. Russell [Australie] ; J. R. Carapetis [Australie] ; A. Balloch [Australie] ; P. V. Licciardi [Australie] ; A. W. J. Jenney [Australie] ; L. Tikoduadua [Fidji] ; L. Waqatakirewa [Fidji] ; J. Pryor [Fidji] ; J. Nelson [Australie] ; G. B. Byrnes [France] ; Y. B. Cheung [Singapour] ; M. L. K. Tang [Australie] ; E. K. Mulholland [Australie, Royaume-Uni]Hyporesponsiveness to re-challenge dose following pneumococcal polysaccharide vaccine at 12 months of age, a randomized controlled trial
002A69 F. M. Russell [Australie] ; A. Balloch [Australie] ; M. L. K. Tang [Australie] ; J. R. Carapetis [Australie] ; P. Licciardi [Australie] ; J. Nelson [Australie] ; A. W. J. Jenney [Australie] ; L. Tikoduadua [Fidji] ; L. Waqatakirewa [Fidji] ; J. Pryor [Fidji] ; G. B. Byrnes [France] ; Y. B. Cheung [Singapour] ; E. K. Mulholland [Australie, Royaume-Uni]Immunogenicity following one, two, or three doses of the 7-valent pneumococcal conjugate vaccine
003132 Janet E. Mcelhaney [États-Unis, Canada] ; Jan P. Dutz [Canada] ; David Holland [Nouvelle-Zélande] ; Robert Booy [Australie] ; Ferdinandus De Looze [Australie] ; Peter Eizenberg [Australie] ; James Mcdonald [Australie] ; Jeff Karrasch [Australie] ; Maureen Mckeirnan [Australie] ; Hatem Salem [Australie] ; Graham Mills [Nouvelle-Zélande] ; Jim Reid [Nouvelle-Zélande] ; Francoise Weber [France] ; Melanie Saville [France]Intradermal Influenza Vaccine Administered Using a New Microinjection System Produces Superior Immunogenicity in Elderly Adults : A Randomized Controlled Trial. Commentary
003F63 Scott Kitchener [Australie] ; Michael Nissen [Australie] ; Peter Nasveld [Australie] ; Remi Forrat [France] ; Sutee Yoksan [Thaïlande] ; Jean Lang [France] ; Jean-Francois Saluzzo [France]Immunogenicity and safety of two live-attenuated tetravalent dengue vaccine formulations in healthy Australian adults
005A60 David E. Briles [États-Unis] ; Susan K. Hollingshead [États-Unis] ; Gary S. Nabors [États-Unis] ; James C. Paton [Australie] ; Alexis Brooks-Walter [États-Unis]The potential for using protein vaccines to protect against otitis media caused by Streptococcus pneumoniae
005C53 Catherine J. Lees [Australie] ; Vasso Apostolopoulos [Australie] ; Bruce Acres [France] ; Ian Ramshaw [Australie] ; Alistair Ramsay [Australie] ; Chin-Swee Ong [Australie] ; Ian F. C. Mckenzie [Australie]Immunotherapy with mannan-MUC1 and IL-12 in MUC1 transgenic mice
006304 C. F. Ockenhouse [États-Unis, Royaume-Uni, France, Australie, Japon] ; P.-F. Sun ; D. E. Lanar ; B. T. Wellde ; B. T. Hall ; K. Kester ; J. A. Stoute ; A. Magill ; U. Krzych ; L. Farley ; R. A. Wirtz ; J. C. Sadoff ; D. C. Kaslow ; S. Kumar ; L. W. P. Church ; J. M. Crutcher ; B. Wizel ; S. Hoffman ; A. Lalvani ; A. V. S. Hill ; J. A. Tine ; K. P. Guito ; C. De Taisne ; R. Anders ; T. Horii ; E. Paoletti ; W. R. BallouPhase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria
006336 R. Khanna [Australie] ; P. Busson [France] ; S. R. Burrows [Australie] ; C. Raffoux [France] ; D. J. Moss [Australie] ; J. M. Nicholls [Hong Kong] ; L. Cooper [Australie]Molecular characterization of antigen-processing function in nasopharyngeal carcinoma (NPC): Evidence for efficient presentation of Epstein-Barr virus cytotoxic T-cell epitopes by NPC cells
006460 C. A. White [Australie] ; S. A. Thomson [Australie] ; L. Cooper [Australie] ; P. M. Van Endert [France] ; R. Tampe [Allemagne] ; B. Coupar [Australie] ; L. Qiu [Australie] ; P. G. Parsons [Australie] ; D. J. Moss [Australie] ; R. Khanna [Australie]Constitutive transduction of peptide transporter and HLA genes restores antigen processing function and cytotoxic T cell-mediated immune recognition of human melanoma cells

Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024